Non-invasive assessment of fluid responsiveness to guide fluid therapy in patients with sepsis in the emergency department: a prospective cohort study

Nienke K Koopmans,1 Renate Stolmeijer,2 Ben C Sijtsma,1 Paul A van Beest,3 Christiaan E Boerma,4 Nic J Veeger,5,6 Ewoud ter Avest

ABSTRACT

Background Little is known about optimal fluid therapy for patients with sepsis without shock who present to the ED. In this study, we aimed to quantify the effect of a fluid challenge on non-invasively measured Cardiac Index (CI) in patients presenting with sepsis without shock.

Methods In a prospective cohort study, CI, stroke volume (SV) and systemic vascular resistance (SVR) were measured non-invasively in 30 patients presenting with sepsis without shock to the ED of a large teaching hospital in the Netherlands between May 2018 and March 2019 using the ClearSight system. After baseline measurements were performed, a passive leg raise (PLR) was done to simulate a fluid bolus. Measurements were then repeated 30, 60, 90 and 120 seconds after PLR. Finally, a standardised 500 mL NaCl 0.9% intravenous bolus was administered after which final measurements were done. Fluid responsiveness was defined as >15% increase in CI after a standardised fluid challenge.

Measurements and main results Seven out of 30 (23%) patients demonstrated a >15% increase in CI after PLR and after a 500 mL fluid bolus. Fluid responders had a higher estimated glomerular filtration rate (eGFR) (64 (44–78) vs 37 (23–47), p=0.009) but otherwise similar patient and treatment characteristics as non-responders. Baseline measurements of cardiac output (CO), CI, SV and SVR were unrelated to PLR fluid responsiveness. The change in CI after PLR was strongly positive correlated to the change in CI after a 500 mL NaCl 0.9% fluid bolus (r=0.88, p<0.001).

Conclusion The results of the present study demonstrate that in patients with sepsis in the absence of shock, three out of four patients do not demonstrate a clinically relevant increase in CI after a standardised fluid challenge. Non-invasive CO monitoring in combination with a PLR test has the potential to identify patients who might benefit from fluid resuscitation and may contribute to a better tailored treatment of these patients.

INTRODUCTION

Sepsis results in over 75 000 hospital admissions and over 15 000 deaths each year in the UK.1 The high disease burden and the perception that sepsis-associated death is preventable2 3 has resulted in the development of specific tools for early recognition and treatment of sepsis.4 5 For these patients with septic shock, early antibiotics and intravenous fluids are the cornerstones of their treatment, although massive crystalloid transfusion is no longer advocated.6 7 Invasive cardiac output (CO) measurement is often applied in these patients to acquire dynamic variables of fluid responsiveness such as changes in CO and Cardiac Index (CI) in response to fluid administration, in order to guide treatment.8

The majority of patients with sepsis presenting to the ED, however, do not fulfil the criteria for septic shock,9 and little is known about optimal fluid therapy for these patients. Previous studies have shown that intravenous fluids are often administered to patients with sepsis in the absence of organ failure or shock.10 The effect on dynamic circulatory parameters, however, is largely unknown, as invasive haemodynamic monitoring is usually not performed. Although positive effects of intravenous fluid administration on static haemodynamic
parameters such as mean arterial pressure (MAP) and heart rate have been reported, it is well recognised that these static measures are not related to outcome. In recent years, however, non-invasive methods to measure CO reliably have become available. This provides the opportunity to monitor dynamic circulatory parameters in a broader category of patients.

In this study, we aimed to quantify the effect of a fluid challenge on non-invasively measured CI in patients presenting with sepsis without shock. Furthermore, we aimed to identify differences in patient or treatment characteristics between fluid responders and non-responders.

METHODS
Study setting and design
We performed a single centre prospective study in patients with sepsis at presentation to the ED of the Medical Center Leeuwarden (a teaching hospital in the Netherlands with 27 000 ED visits yearly) between May 2018 and March 2019.

Study population
Patients were eligible to participate if they presented to the ED with sepsis. In line with sepsis-3 guidelines, there had to be evidence of an infection (defined as a temperature <36°C or >38°C without an obvious cause for hypothermia or hyperthermia) in combination with evidence of organ dysfunction (defined as the presence of at least one of the quick sepsis-related organ failure assessment (qSOFA) criteria (altered mental state, hypotension (MAP <65 mm Hg) or systolic blood pressure (SBP) <100 mm Hg) or a respiratory rate >22/min) or hypoxemia (oxygen saturation (SpO₂) <94% or 5% lower than baseline) or a lactate >2.1 mmol/L in point of care arterial blood gas analysis or venous blood gas analysis performed directly at presentation). Other signs of organ dysfunction requiring continuous observation and/or lab results not immediately available at presentation (eg, acute renal dysfunction, coagulopathy, hyperbilirubinemia, decreased urinary output) were not used for sepsis definition (and thereby patient selection).

Patients could not participate when they were <16 years, when they had a (presumed) increased abdominal pressure (including pregnant women) or when they presented with a concurrent acute event requiring immediate medical, endovascular or surgical intervention (cerebral events, acute coronary syndrome, acute pulmonary oedema, status asthmaticus, active gastrointestinal bleeding or trauma). Patients with known metastatic cancer in a palliative setting were excluded in order to minimise length of stay for these patients in the ED.

Patients with septic shock (ie, those who remained hypotensive after fluid bolus administration or needing vasopressor therapy to obtain a MAP >65 mm Hg in the presence of a lactate >2.1 mmol/L) and subjects for whom it was impossible to measure CO reliably in a non-invasive manner were excluded.

Non-invasive CO measurements
CO was measured non-invasively using the ClearSight system (Edwards Lifesciences, Irvine, California, USA). The methodology of the ClearSight is based on the pulsatile unloading of the finger arterial walls using an inflatable finger cuff with a built-in photoelectric plethysmograph that uses pressure to maintain a constant blood volume in the finger. ClearSight calculates beat-to-beat stroke volume (SV) by dividing the area under the SBP curve (measured at 200 Hz) by the aortic input impedance (Zin). The value of Zin is determined from a three-element Windkessel model in which the non-linear effect of MAP and the influence of the patient’s age, height, weight and gender on aortic mechanical properties are incorporated. Because the waveform at the finger shows a more undulatory appearance than the radial pressure waveform, the system transforms the finger waveform into a brachial waveform with a specific filter. ClearSight uses the integrated area under the pulsatile systolic waveform from the brachial pressure wave as an input to the model, which directly yields SV and produces CO by multiplying beat-to-beat SV by instantaneous heart rate. The Nexfin technology used in the ClearSight has been shown to, although not interchangeable with transpulmonary thermodilution, be convenient and consistent to continuously measure CI, and could track the direction of changes under dynamic conditions.

Study procedures
The finger cuff of the ClearSight system was applied to the patients finger as soon as possible after arrival in the ED and after consent was obtained, but no sooner than 5 min after transfer to the ED trolley. This was to minimise adrenergic stimulation by anxiety or pain. After the system was calibrated and a reliable signal was obtained, three baseline readings were done for CO, CI, SV and systemic vascular resistance (SVR), separated by 1 min intervals. Subsequently, a standardised passive leg raise (PLR) test was performed by to simulate a fluid bolus. The PLR test induces an auto transfusion of around 300 mL of fluids. Patients started in a semirecumbent position under 45°. The body is then moved in a full supine position with subsequent positioning of both legs raised at 45° from the bed for 120 s, and measurements of CO, CI, SV and SVR were repeated after 30, 60, 90 and 120 s via the ClearSight device (online supplemental figure 1). Thereafter, the patient was returned to his/her original position and after 120 s a new baseline reading was done. In accordance with literature, a cut-off value of 15% increase in CI after PLR was used to differentiate between fluid responders and non-responders. Finally, all patients were administered 500 mL NaCl 0.9% intravenously over a duration of 15 min.

After finishing the fluid challenge for 120 s, CO, CI, SV and SVR were measured for a last time (figure 1).

Data collection
The following parameters were collected on a dedicated case report form: patient demographics, prehospital data (oxygen and fluid administration, duration of symptoms, antibiotic treatment), vital parameters at presentation, (POCT)-lab results, presumed source of infection and non-invasive circulatory parameters at presentation, directly after PLR test and after a standardised fluid challenge. The sepsis warning and severity scores Systemic Inflammatory Response Score, Modified Early Warning Score (MEWS), National Early Warning Score (NEWS), qSOFA and Pneumonia Severity Score (CURB-65) scores were calculated based on information available at presentation, and patient disposition, patient re-disposition to intensive care unit within 48 hours and mortality within 30 days were extracted from the hospital’s electronic patient record (EPIC).

Outcomes
The primary outcome was defined as the percentage of subjects in whom a standardised simulated fluid bolus by a PLR test resulted in a 15% or more improvement in non-invasively measured CI.

Secondary outcomes were defined as the relation between the changes in CI after respectively PLR and a standardised fluid bolus of 500 mL NaCl 0.9%, the relation between


417

baseline CI, CO, SVR and SV with the change in CI after respectively PLR and a standardised fluid bolus and as the difference in patient or treatment characteristics between fluid responders and non-responders.

**Sample size**
Sample size was calculated based on CO, as no prior trials were conducted with CI as primary outcome measure in similar populations. As CI is more frequently used than CO in clinical practice, we choose CI as our primary endpoint. Normal CO is variable between 4.0 and 8.0 L/min.\(^{16}\) Assuming a mean CO of 5.5 L/min, we estimated 30 patients were needed to detect a (clinically relevant) difference of 0.8±1.4 L/min (15% increase) after a pre-load modifying manoeuvre with a power of 90% and an alpha of 0.05.\(^{17}\) Accounting for a 10% attrition rate, it was decided to recruit 35 patients.

**Data analysis**
Patient and treatment characteristics (including CO, CI, SV and SVR) are presented as median (IQR) or counts (%). Changes in CI in response to PLR or fluid administration were assessed using paired t-test (described as means (95% CI)) or Wilcoxon signed rank test (described as medians (IQR), whichever was appropriate. When comparing patient characteristics and responses of fluid responders versus non-responders, a Mann-Whitney U test and (exact) \(\chi^2\) or Fisher’s exact test was used, where appropriate. Univariate correlation coefficients for CI, CO, SV and SVR after PLR and after fluid bolus administration were calculated. Missing data were reported in the Results section according to the Strengthening the Reporting of Observational Studies in Epidemiology guideline.\(^{18}\) A p value <0.05 was considered statistically significant. All statistical analyses were conducted with SAS software, V.9.4 (SAS Institute).

Pre-planned sensitivity analysis based on prehospital fluid administration was performed. Additionally, a pre-planned sensitivity analysis was performed assuming that the excluded patients were either all fluid responders or non-responders.

**Patient and public involvement**
This research was done without patient involvement. Patients were not invited to comment on the study design and were not consulted to develop patient relevant outcomes or interpret the results. Patients were not invited to contribute to the writing or editing of this document for readability or accuracy.

---

**Figure 1** Overview of study procedures. CI, Cardiac Index; CO, cardiac output; PLR, passive leg raise; SV, stroke volume; SVR, systemic vascular resistance.

**Figure 2** Patient inclusion. PLR, passive leg raise.
**RESULTS**

**Study population**

During the study period, 53 ED patients with sepsis were screened for inclusion. In nine patients, PLR was not possible due to painful or amputated legs, two patients were on dialysis and was excluded under the presumption of septic shock (figure 2). One patient had to be excluded after completion of the measurements due to incomplete PLR results (missing t = 30 s measurement), leaving 30 patients for the final analysis of the primary endpoint.

Median age of the patients was 75 (68–83) years. The majority of patients had a pulmonary (n=12) or urological (n=14) source of their infection. Seven (23%) of the patients had a >15% increase in CI after fluid bolus administration.

**Sensitivity analyses**

Four patients received prehospital fluids, all of whom were fluid responders. Sensitivity analysis including only patients who had received any prehospital fluid (n=26) did not change the primary outcome: (baseline CI 3.3 (2.5–3.9) L/min/m², 3.3 (2.8–4.1) L/min/m² after PLR (average change 0.22±0.39 L/min/m², p=0.009) and 3.3 (2.8–3.8) L/min/m² (average change 0.12±0.43 L/min/m², p=0.17) after fluid bolus administration).

**Patient, treatment and disease characteristics in relation to fluid responsiveness**

Patients responding with a >15% increase in CI after PLR (responders) were older (82 (73–85) vs 73 (68–83) years, p=0.07) although none of these comparisons was statistically significant. However, estimated Glomerular Filtration Rate (eGFR) was significantly higher in non-responders (64 (44–78) vs 34 (20–69) ml/min/m², p=0.003). PLR resulted in a 15% or greater increment in CI in 7/30 (23%) of the patients. Median maximum CI after the 500 mL NaCl 0.9% fluid challenge was 3.3 (2.8–3.9) L/min/m² (mean (95% CI) change 0.12 (−0.36 to 0.28) L/min/m², p=0.127). As with PLR, the fluid bolus resulted in a >15% increase in CI in 7/30 (23.3%) of the patients.

**Analysis of outcome measures**

**Fluid responsiveness after PLR and fluid bolus**

Median (IQR) CI was 3.3 L (2.5–4.0)/min/m² at baseline. For most patients, CI peaked 30 s after the start of the PLR procedure (figure 3). Median maximum CI was 3.4 (2.8–4.2) L/min/m², (mean (95% CI) change compared with baseline 0.22 (0.09–0.36) L/min/m², p=0.003). PLR resulted in a 15% or greater increment in CI in 7/30 (23%) of the patients. Median maximum CI after the 500 mL NaCl 0.9% fluid challenge was 3.3 (2.8–3.9) L/min/m² (mean (95% CI) change 0.12 (−0.36 to 0.28) L/min/m², p=0.127). As with PLR, the fluid bolus resulted in a >15% increase in CI in 7/30 (23.3%) of the patients.

**Sensitivity analyses**

Four patients received prehospital fluids, all of whom were fluid responders (online supplemental table 1). Sensitivity analysis including only patients who had not received any prehospital fluid (n=26) did not change the primary outcome: (baseline CI 3.3 (2.5–3.9) L/min/m², 3.3 (2.8–4.1) L/min/m² after PLR (average change 0.22±0.39 L/min/m², p=0.009) and 3.3 (2.8–3.8) L/min/m² (average change 0.12±0.43 L/min/m², p=0.17) after fluid bolus administration).

**Analysis of outcome measures**

**Fluid responsiveness after PLR and fluid bolus**

Median (IQR) CI was 3.3 L (2.5–4.0)/min/m² at baseline. For most patients, CI peaked 30 s after the start of the PLR procedure (figure 3). Median maximum CI was 3.4 (2.8–4.2) L/min/m², (mean (95% CI) change compared with baseline 0.22 (0.09–0.36) L/min/m², p=0.003). PLR resulted in a 15% or greater increment in CI in 7/30 (23%) of the patients. Median maximum CI after the 500 mL NaCl 0.9% fluid challenge was 3.3 (2.8–3.9) L/min/m² (mean (95% CI) change 0.12 (−0.36 to 0.28) L/min/m², p=0.127). As with PLR, the fluid bolus resulted in a >15% increase in CI in 7/30 (23.3%) of the patients.
Fluid therapy for sepsis has become more restrictive over the recent years after publication of the ProMISE, ARISE, Process and FEAST trials that showed no benefit of early goal directed therapy,\textsuperscript{19–21} or even potential harm of fluid bolus administration.\textsuperscript{22} However, to date most guidelines\textsuperscript{23, 24} still recommend early intravenous fluid administration to hypotensive sepsis patients to correct overt hypovolemia under the presumption that this may improve CO, oxygen delivery and organ function.

In these guidelines, the administration of an initial intravenous crystalloid bolus of up to 30 mL/kg of body weight is recommended as a reasonable first step in the haemodynamic management of an adult patient with septic shock.\textsuperscript{24} These guidelines, however, do not provide clear recommendations for patients with sepsis who are not in shock: Although some guidelines mention that intravenous fluids should be considered, it is not mentioned when, nor how much fluids should be administered.

Our findings demonstrate that a simulated fluid bolus of around 300 mL does not result in a clinically relevant increase in CI in the majority of patients with sepsis without shock. This could not be explained by the volume of the simulated fluid bolus, as previous studies in other populations have revealed that PLR-induced changes in CO can reliably predict fluid responsiveness regardless of ventilation mode and cardiac rhythm.\textsuperscript{25}

An alternative explanation is that increases in preload do not automatically translate in an increase in CI: the relation between preload and CI as represented in the Frank-Starling curve\textsuperscript{26} is modified by the complex interaction of multiple components of the cardiovascular system, such as systemic filling pressure, right atrial pressure, venous resistance, ventricular compliance, cardiac contractility and afterload.\textsuperscript{7, 9} PLR may affect many of these components concurrently and some of these even in a negative direction (eg, by increasing right atrial pressure and thereby decreasing venous return). The ultimate effect of PLR on CI is the result of all of these effects, and may vary from person to person. In addition, cardiovascular medication use may modify the relationship between preload and CI. As previous literature has shown that patients with uncomplicated sepsis receive on average 680 mL of intravenous fluids in the first 2 hours of their ED stay,\textsuperscript{10} our findings may indicate that this treatment may not improve haemodynamic status for many of these patients.

In this study, in three out of four patients with sepsis without shock haemodynamic status remained unchanged in response to fluid resuscitation. This is far more than the one in three reported

**Table 2** Baseline values of Cardiac Index, stroke volume and systemic vascular resistance of ED patients presenting with uncomplicated sepsis stratified by their response (>15% increase) in Cardiac Index after a passive leg raise (n=30)

<table>
<thead>
<tr>
<th></th>
<th>Responders (n=7)</th>
<th>Non-responders (n=23)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Baseline CI (L/min/m²)</td>
<td>3.3 (1.9–3.8)</td>
<td>3.3 (2.7–4.0)</td>
<td>0.40</td>
</tr>
<tr>
<td>Baseline SV (mL)</td>
<td>63 (44–69)</td>
<td>61 (49–80)</td>
<td>0.73</td>
</tr>
<tr>
<td>Baseline SVR (dyn.s/cm⁵)</td>
<td>800 (750–1354)</td>
<td>816 (719–1095)</td>
<td>0.88</td>
</tr>
</tbody>
</table>

SV stroke volume; CI, Cardiac Index; SVR, systemic vascular resistance.

**Figure 4** Scatterplots of maximum change in Cardiac Index after passive leg raise versus baseline cardiac output, Cardiac Index, stroke volume and systemic vascular resistance (n=30). CI, Cardiac Index; CO, cardiac output; PLR, passive leg raise; SV, stroke volume; SVR, systemic vascular resistance.

**Figure 5** Scatterplot of paired data of individual patients of Cardiac Index after passive leg raise versus Cardiac Index after administration of a standardised intravenous fluid bolus of 500 mL NaCl 0.9% in ED patients with uncomplicated sepsis (n=30). CI, Cardiac Index; ED, emergency department; NS, NaCl 0.9%; PLR, passive leg raise test.
by Leisman et al\textsuperscript{22} in their study of hypotensive sepsis patients. Unfortunately, we were not able to predict which patients would benefit from fluid administration based on patient characteristics at presentation in the ED. There was a trend for responders to have higher urea and creatinine blood concentrations, but significance was only reached for eGFR. These findings may suggest that hydration status and/or intravascular volume status (ie, point on the Frank starling curve) may be a determinant of the effect of increasing preload on SV (and thereby CO and CI): the more a patient is dehydrated, the more likely a PLR or a fluid bolus is to increase CI by increasing SV.

Fluid responders tended to be older and to have a lower HR. This may indicate that although elderly patients benefit from fluid administration (as they increase their CO), their HR response may be blunted (eg, by pathophysiological changes or medication use). This is in line with a previous study wherein it was demonstrated that fluid requirement is higher for elderly patients with an infection compared with younger patients.\textsuperscript{26} In this regard it is important to mention that the average age (75) of our study population was high compared with other populations.\textsuperscript{23,27} If and how this has affected our study results is difficult to predict, as not only fluid requirement may be higher in the elderly, but fluid responsiveness may as well be related to age (eg, due to the higher prevalence of pre-load dependent comorbidities as atrial fibrillation).

The finding that static measurements of SV, SVR, CO and CI at baseline could not predict fluid responsiveness may well be explained by the fact that these measurements not only reflect fluid status, but also cardiovascular status, including myocardial/valvular function and overall vascular tone. On the contrary, we demonstrate that dynamic fluid status assessment with PLR can be used as a reliable predictor to test which patients presenting with sepsis in the ED would benefit from fluid administration, as the correlation between changes in CI between PLR and fluid bolus (500 mL NaCl 0.9\%) was high (r=0.88). Non-invasive CO monitoring in combination with PLR may therefore be a valuable new tool to help the clinician tailor sepsis treatment to individual patients, especially in elderly patients. This is of increasing importance as the prevalence of sepsis is rising,\textsuperscript{29} and the average sepsis patient presenting in the ED of most western countries is not only getting older, but also has more comorbidities requiring careful consideration of all treatment options.

Our study has several important limitations. First, although we compared patient, disease and treatment characteristics of responders and non-responders to PLR, some variables (such as fluid intake (and administration) in the days prior to ED presentation, cardiovascular comorbidities (especially LVF and RVF, both in systole and diastole) and cardiovascular medication use (especially beta-blocking drugs)) were not recorded. As fluid responsiveness to PLR is dependent both on preload and cardiac function, our findings may have been influenced by comorbidities and/or cardiovascular medication use. Second, our study carries the potential of sampling bias, as we conducted our study in a convenience sample of ED patients with sepsis but not septic shock. Shift hours (night-time vs daytime), ED crowding and other factors might have influenced patient selection and thereby outcome, which affects generalisability of our results. Generalisability is further affected by inclusion criteria, as we relied on temperature <36 or >38\textdegree C without an obvious cause for the hypothermia or hyperthermia to define the presence of an infection. Third, since no point-to-point individual data were available from previous studies, our sample size calculation was based on the overall response rather than our predefined individual primary endpoint. In addition, our study lacks a control arm and therefore we cannot rule out a change in CI in the absence of PLR or fluid bolus. Finally, the number of patients that had to be excluded due to an inability to either fit the finger cuff (1) or obtain a reliable signal (6) to measure CI non-invasively was substantial and may have resulted in selection bias. Although the Clearsight technology has been shown to be a reasonable alternative to invasive monitoring for the assessment of trends in CO,\textsuperscript{12,13} one has to obtain a reliable signal first. This may also limit the practical use of non-invasive output measurements to guide fluid therapy in patients presenting in the ED with uncomplicated sepsis.

Conclusion
The results of the present study demonstrate that in patients with sepsis in the absence of shock, three out of four patients are unresponsive to a standardised fluid challenge. Non-invasive CO monitoring in combination with a PLR test has the potential to identify patients who might benefit from fluid resuscitation and may contribute to better tailored treatment.

Twitter Ewoud ter Avest @ewoudteravest

Contributors EtA conceived the study and designed the trial. EtA and NKK obtained research funding. ECB and PAvB advised on study design and data interpretation. NKK, BC5 and RS undertook recruitment of patients and acquired the data. NKK and EtA managed the data including quality control. Statistical analysis was performed by NIV and NKK. NIK and EtA drafted the manuscript. All authors revised the manuscript critically and gave final approval to submission of the manuscript. EtA takes responsibility for the paper as a whole.

Funding This study received a grant from the SGO-foundation, and from the Medical Center Leeuwarden. Funding institutions had no role in conception, design or conduct of the study; collection, management, analysis, interpretation or presentation of the data; or preparation, review or approval of the manuscript.

Competing interests The authors received unrestricted grants from the Dutch Emergency Medicine Research fund (SGO-fonds) and the Medical Center Leeuwarden research fund for conducting this study.

Patient consent for publication Not required.

Ethics approval The local Medical Ethics Committee (RTFO) reviewed the study protocol prior to the start of the study (RTFO No. nwMO 271) and decided that, in accordance with Dutch law, the study met criteria for exempt research. Informed consent was sought and obtained from all patients before participation in the study. The study was registered at ClinicalTrials.gov before the start of the study (registration number NCT03728998).

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement Deidentified participant data and additional information (study protocol) are available upon reasonable request from the corresponding author.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/.
Original research


